Cipla (CIPLA) — Board Meeting

Cipla reported consolidated revenue of ₹6,957.47 crores for Q1 FY2025, up 32% YoY, driven by strong pharmaceutical sales, while net profit reached ₹1,291.61 crores, a 6% YoY increase. The board approved unaudited results showing total income of ₹7,216.03 crores and profit before tax of ₹1,769.93 crores, reflecting robust operational performance and improved margins.

📄 View Original Announcement (PDF)

📊 Stock Analysis — CIPLA ✨ Ask AI About This

About Cipla Limited (CIPLA)

Healthcare · Pharmaceuticals & Biotechnology · Listed on NSE

Market Cap: ₹1,15,682.55 Cr P/E: 25.4 ROE: 14.6% ROCE: 19.4%

View full CIPLA stock details →

📡 Get AI alerts when CIPLA files next

Free • Daily 5 PM digest • Track filings, board meetings, and corporate actions

Track CIPLA — Free

💡 Ask AI about this filing

"How does this board meeting affect Cipla Limited's outlook?" "What did Cipla Limited announce on 25 July 2025?" "Is this positive or negative for CIPLA?"

Ask AI Free →

📊 More CIPLA filings

See all CIPLA filings →

🔥 Also filed on 25 July 2025

SHRIRAMFIN Shriram Finance Limited Financial Results SBICARD SBI Cards and Payment Services Limited Financial Results SBICARD SBI Cards and Payment Services Limited Financial Results RECLTD REC Limited Financial Results SHRIRAMFIN Shriram Finance Limited Financial Results SRF SRF Limited Corporate Action

View all today's announcements →

Source: Stock Announcements. Analysis by StockFin.ai. For informational purposes only — not investment advice.

Editorial & Data Transparency Notice

This analysis was programmatically compiled using StockFin AI utilizing official regulatory disclosures from the BSE and NSE. Content is automatically synthesized and audited against public financial filings. StockFin.ai is an educational research platform and is NOT a SEBI-registered investment advisor or research analyst.

📡 Get AI alerts when CIPLA files new disclosures

Track CIPLA filings, board meetings, and corporate actions. Free email alerts at 5 PM.